An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer. Read more here.
Study mentioned: Armstrong AJ, et al. Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2013 Nov 19. [Epub ahead of print] PMID: 24255071
No comments:
Post a Comment